Xilio Therapeutics, Inc. (XLO): Cash & Equivalents
$137.53M
As of 2025-12-31
$136.04M
As of 2026-06-30
+4.5%
3-year compound annual growth
+48.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $137.53M | +148.7% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $55.29M | +23.7% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $44.70M | -62.9% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $120.39M | -39.2% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $198.05M | +929.5% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $19.24M | n/a | 2022-03-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $4.47M | +23.7% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $602.07M | +99.3% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $6.39M | +8.2% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $120.72M | -49.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $128.39M | +32.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
Compare XLO, INBP, CPIX, WVE side by side · Screen every company in Pharmaceutical Preparations ↗